title: RU 29 246, the active compound of the cephalosporin prodrug-ester HR 916. III. Pharmacokinetic properties and antibacterial activity in vivo.
abstract: The pharmacokinetics of the broad spectrum cephem RU 29 246 and its prodrug-ester HR 916 B were investigated in mice, rats and dogs and compared to those of cefpodoxime proxetil, cefuroxime axetil and cefixime. HR 916 B is well absorbed following oral administration and efficiently converted to the antibacterially active form. In mice, mean peak blood levels of 31.1 micrograms/ml of the parent compound were recorded within 20 minutes after oral administration of a single dose equivalent to 40 mg/kg RU 29 246. The bioavailability calculated on the basis of the areas under the concentration-time curves (AUC) and the urinary recoveries was about 90%. In rats, peak blood levels of 14.5 micrograms/ml were obtained 1 hour after an oral 20 mg/kg dose. The bioavailability was calculated as 70%. In dogs, 40% of an oral 10 mg/kg dose was recovered in the urine within 24 hours. Cmax was 15.9 micrograms/ml at 4.6 hours. Mean elimination half-lives of RU 29 246 were 0.35, 0.5 and 2.1 hours in mice, rats and dogs, respectively. After an oral HR 916 B dose equivalent to 50 mg/kg of RU 29 246, tissue concentrations at 0.5 hour ranged between 0.8 micrograms/g in brain and 95.7 micrograms/g in murine kidneys. These values of HR 916 B are similar to, or distinctly higher than, those of the reference compounds. Of the oral cephalosporins tested, HR 916 B had the most balanced antibacterial spectrum. With ED50s of between 0.9 and 11.5 mg/kg against staphylococci, its activity was similar to that of the additional reference compound cefaclor and higher than that of cefuroxime. Cefixime and cefpodoxime proxetil displayed low antistaphylococcal activity or were inactive. In septicemias with Enterobacteriaceae, cefixime and cefpodoxime proxetil were more potent than HR 916 B and cefaclor. Cefuroxime axetil was inactive against most of these infections. HR 916 B was also highly effective against murine lung infections caused by Klebsiella pneumoniae DT-S or Streptococcus pneumoniae 1147.
authors.affiliation: Hoechst AG, Frankfurt/Main, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Klesel
authors.forename: F
authors.initials: F
authors.lastname: Adam
authors.forename: D
authors.initials: D
authors.lastname: Isert
authors.forename: M
authors.initials: M
authors.lastname: Limbert
authors.forename: A
authors.initials: A
authors.lastname: Markus
authors.forename: E
authors.initials: E
authors.lastname: Schrinner
authors.forename: G
authors.initials: G
authors.lastname: Seibert
mesh_terms: D000818:Animals; D002511:Cephalosporins / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004285:Dogs; D005260:Female; D008297:Male; D051379:Mice; D011014:Pneumonia / Q000188:drug therapy; D011355:Prodrugs / Q000493:pharmacokinetics*; D051381:Rats; D011919:Rats, Inbred Strains; D018805:Sepsis / Q000188:drug therapy; D014018:Tissue Distribution
chemical_list: D002511:Cephalosporins; D011355:Prodrugs; C073743:RU 29246